These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8330926)

  • 1. Effect of a series of 1-alkyl ether lipids on inhibition of phospholipase A2 activity and PAF responses.
    Kohler C; Carroll M; Tarrant E; Torley L; Wissner A
    Inflammation; 1993 Jun; 17(3):245-61. PubMed ID: 8330926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation.
    Ribaldi E; Mezzasoma AM; Francescangeli E; Prosdocimi M; Nenci GG; Goracci G; Gresele P
    Br J Pharmacol; 1996 Jul; 118(6):1351-8. PubMed ID: 8832056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that 85 kDa phospholipase A2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes.
    Winkler JD; Bolognese BJ; Roshak AK; Sung CM; Marshall LA
    Biochim Biophys Acta; 1997 Jun; 1346(2):173-84. PubMed ID: 9219900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Groups I, II and III extracellular phospholipases A2: selective inhibition of group II enzymes by indomethacin but not other NSAIDs.
    Lobo IB; Hoult JR
    Agents Actions; 1994 Mar; 41(1-2):111-3. PubMed ID: 8079814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and topical in vivo inflammatory murine models in the evaluation of inhibitors of phospholipase A2.
    Glaser KB; Sung ML; Hartman DA; Lock YW; Bauer J; Walter T; Carlson RP
    Skin Pharmacol; 1995; 8(6):300-8. PubMed ID: 8688196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2).
    Glaser KB; Carlson RP; Sung A; Bauer J; Lock YW; Holloway D; Sturm R; Hartman D; Walter T; Woeppel S
    Agents Actions; 1993; 39 Spec No():C30-2. PubMed ID: 8273577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y; Imanishi N; Uchida M; Morooka S
    Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds.
    Hogaboam CM; Donigi-Gale D; Shoupe TS; Bissonnette EY; Befus AD; Wallace JL
    Br J Pharmacol; 1992 Jan; 105(1):87-92. PubMed ID: 1596692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
    Hwang SB; Li CL; Lam MH; Shen TY
    Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human recombinant phospholipase A2 inhibits platelet aggregation in vitro and in vivo in rat and guinea pig.
    Cirino G; Cicala C; Sorrentino R; Sorrentino L; Browning JL; Page CP
    Eur J Pharmacol; 1994 Feb; 252(2):147-54. PubMed ID: 8157055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of inflammatory responses by surfactin, a selective inhibitor of platelet cytosolic phospholipase A2.
    Kim K; Jung SY; Lee DK; Jung JK; Park JK; Kim DK; Lee CH
    Biochem Pharmacol; 1998 Apr; 55(7):975-85. PubMed ID: 9605421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of carrageenin-induced rat paw oedema by crotapotin, a polypeptide complexed with phospholipase A2.
    Landucci EC; Antunes E; Donato JL; Faro R; Hyslop S; Marangoni S; Oliveira B; Cirino G; de Nucci G
    Br J Pharmacol; 1995 Feb; 114(3):578-83. PubMed ID: 7537590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of interleukin 1alpha on superoxide anion, platelet activating factor release and phospholipase A2 activity of naive and sensitized guinea-pig alveolar macrophages.
    Mugnai S; Ciuffi M; Maurizi M; Bindi D; Franchi-Micheli S; Zilletti L
    Br J Pharmacol; 1997 Dec; 122(7):1345-52. PubMed ID: 9421281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock.
    Marshall LA; Hall RH; Winkler JD; Badger A; Bolognese B; Roshak A; Flamberg PL; Sung CM; Chabot-Fletcher M; Adams JL
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1254-62. PubMed ID: 7562496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation.
    Marshall LA; Winkler JD; Griswold DE; Bolognese B; Roshak A; Sung CM; Webb EF; Jacobs R
    J Pharmacol Exp Ther; 1994 Feb; 268(2):709-17. PubMed ID: 8113982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oedema formation and degranulation of mast cells by phospholipase A2 purified from porcine pancreas and snake venoms.
    Lloret S; Moreno JJ
    Toxicon; 1993 Aug; 31(8):949-56. PubMed ID: 8212047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guinea-pig and platelet aggregation in man.
    Evans TW; Dent G; Rogers DF; Aursudkij B; Chung KF; Barnes PJ
    Br J Pharmacol; 1988 May; 94(1):164-8. PubMed ID: 3401633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new phospholipase A2 inhibitor, unrelated to substrate analogues: kinetic characterization of the inhibition of secretory phospholipases A2 by PMS 832.
    Binisti C; Mounier C; Touboul E; Heymans F; Bon C; Godfroid JJ
    J Lipid Mediat Cell Signal; 1997 Jul; 16(3):171-87. PubMed ID: 9246606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of various phospholipases A2 and inhibitors in the pathogenesis and prevention of pancreatic acinar cell necrosis: studies with isolated rat pancreatic acini.
    Mössner J; Wessig C; Ogami Y; Keim V
    Int J Pancreatol; 2000 Feb; 27(1):29-38. PubMed ID: 10811021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.